{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:01:20Z","timestamp":1793721680194,"version":"4.6.1"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,12]],"date-time":"2017-03-12T00:00:00Z","timestamp":1489276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ejpb.2017.03.006","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T10:32:11Z","timestamp":1489487531000},"page":"14-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":167,"special_numbering":"C","title":["Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts"],"prefix":"10.1016","volume":"117","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Lallemand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Bourges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gurny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Benita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S\u00e9bastien","family":"Garrigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2017.03.006_b0005","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.drudis.2013.12.002","article-title":"Immunosuppressive peptides and their therapeutic applications","volume":"19","author":"Thell","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2017.03.006_b0010","first-page":"299","article-title":"The controversial early history of cyclosporin","volume":"131","author":"Heusler","year":"2001","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.ejpb.2017.03.006_b0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2478\/s11658-008-0041-6","article-title":"Oral cyclosporine A\u2013the current picture of its liposomal and other delivery systems","volume":"14","author":"Czogalla","year":"2009","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.ejpb.2017.03.006_b0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0939-6411(03)00138-3","article-title":"Cyclosporine A delivery to the eye: a pharmaceutical challenge","volume":"56","author":"Lallemand","year":"2003","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2017.03.006_b0025","unstructured":"Novartis, Sandimmune, 2015 (prescribing information)."},{"key":"10.1016\/j.ejpb.2017.03.006_b0030","unstructured":"Novartis, Neoral, 2015 (prescribing information)."},{"key":"10.1016\/j.ejpb.2017.03.006_b0035","first-page":"173","article-title":"Cyclosporin A applied topically to the recipient eye inhibits corneal graft rejection","volume":"45","author":"Hunter","year":"1981","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0040","first-page":"2195","article-title":"Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit model","volume":"18","author":"Liang","year":"2012","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ejpb.2017.03.006_b0045","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/bjo.74.6.350","article-title":"Ocular penetration of cyclosporin A. III: the human eye","volume":"74","author":"BenEzra","year":"1990","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0050","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/0002-9343(84)90356-5","article-title":"Side effects of systemic cyclosporine in patients not undergoing transplantation","volume":"77","author":"Palestine","year":"1984","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejpb.2017.03.006_b0055","series-title":"Mucosal Delivery of Biopharmaceuticals","article-title":"Development of a cationic nanoemulsion platform (Novasorb\u00ae) for ocular delivery","author":"Lallemand","year":"2013"},{"key":"10.1016\/j.ejpb.2017.03.006_b0060","doi-asserted-by":"crossref","first-page":"604204","DOI":"10.1155\/2012\/604204","article-title":"Successfully improving ocular drug delivery using the cationic nanoemulsion, Novasorb","volume":"2012","author":"Lallemand","year":"2012","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.ejpb.2017.03.006_b0065","unstructured":"US Food and Drug Administration, Restasis\u00ae approval package."},{"key":"10.1016\/j.ejpb.2017.03.006_b0070","unstructured":"European Medicines Agency, Ikervis\u00ae authorisation, 2015."},{"key":"10.1016\/j.ejpb.2017.03.006_b0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00003226-199307000-00007","article-title":"Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca","volume":"12","author":"Laibovitz","year":"1993","journal-title":"Cornea"},{"key":"10.1016\/j.ejpb.2017.03.006_b0080","series-title":"Ocular Surface Disease: Cornea, Conjunctiva and Tear Film","author":"Holland","year":"2013"},{"key":"10.1016\/j.ejpb.2017.03.006_b0085","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0002-9394(14)77061-8","article-title":"Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis","volume":"110","author":"Secchi","year":"1990","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfo.2016.12.004","article-title":"Pan-European survey of the topical ocular use of cyclosporine A","author":"Labbe","year":"2017","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0095","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1542-0124(12)70085-X","article-title":"Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop","volume":"5","author":"DEWS","year":"2007","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.ejpb.2017.03.006_b0100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4172\/2155-9570.1000115","article-title":"Safety and efficacy of topical 0.1% and 0.05% cyclosporine A in an aqueous solution in steroid-dependent vernal keratoconjunctivitis in a population of mexican children","volume":"1","author":"Baiza-Duran","year":"2010","journal-title":"J. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0105","unstructured":"Sophia Laboratorios, Modusik-A, 2013 (prescribing information)."},{"key":"10.1016\/j.ejpb.2017.03.006_b0110","unstructured":"Allergan, RESTASIS\u00ae (cyclosporine ophthalmic emulsion) 0.05%, 2014 (prescribing information)."},{"key":"10.1016\/j.ejpb.2017.03.006_b0115","unstructured":"Taejoon Pharm, Product information: Cyporin N eye drop 0.05% (cyclosporin), 2014."},{"key":"10.1016\/j.ejpb.2017.03.006_b0120","unstructured":"US Food and Drug Administration, NADA 141\u2013052 Optimmune\u00ae Ophthalmic Ointment \u2013 Supplemental Approval, 2015 (August 26, 1997)."},{"key":"10.1016\/j.ejpb.2017.03.006_b0125","first-page":"527","article-title":"Cyclosporin A eyedrops: manufacturing, toxicity, pharmacokinetics and indications in 2000","volume":"24","author":"Robert","year":"2001","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0130","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jphp.12075","article-title":"Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery","volume":"66","author":"Daull","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0135","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: the good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ejpb.2017.03.006_b0140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/jop.2015.0054","article-title":"Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping","volume":"32","author":"Daull","year":"2016","journal-title":"J. Ocul. Pharm. Ther."},{"key":"10.1016\/j.ejpb.2017.03.006_b0145","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/1877912311202020082","article-title":"Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery","volume":"2","author":"Cholkar","year":"2012","journal-title":"Recent Pat. Nanomed."},{"key":"10.1016\/j.ejpb.2017.03.006_b0150","first-page":"145","article-title":"The deleterious effect of certain surface active agents on the ocular surface","author":"Ravet","year":"2007","journal-title":"Bull. Soc. Belge Ophtalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0155","unstructured":"Santen, Santen receives Manufacturing and Marketing Approval for its Vernal Keratoconjunctivitis Treatment, PAPILOCK Mini Ophthalmic Solution 0.1%, 2005."},{"key":"10.1016\/j.ejpb.2017.03.006_b0160","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.5897\/AJPP2012.1493","article-title":"Formulation and evaluation of aceclofenac ophthalmic gel","volume":"7","author":"Kumar","year":"2013","journal-title":"Afr. J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0165","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1167\/iovs.08-1880","article-title":"Neurologic evaluation of acute lacrimomimetic effect of cyclosporine in an experimental rabbit dry eye model","volume":"50","author":"Toshida","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2017.03.006_b0170","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.biopha.2004.02.001","article-title":"Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs","volume":"58","author":"Gursoy","year":"2004","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejpb.2017.03.006_b0175","first-page":"79","article-title":"A compositional based model for the tear film lipid layer","volume":"95","author":"McCulley","year":"1997","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"10.1016\/j.ejpb.2017.03.006_b0180","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1136\/bjo.2008.156828","article-title":"Turnover rate of tear-film lipid layer determined by fluorophotometry","volume":"93","author":"Mochizuki","year":"2009","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0185","unstructured":"Bausch & Lomb, Lacrinmune, 2009 (product information; in Spanish)."},{"key":"10.1016\/j.ejpb.2017.03.006_b0190","unstructured":"Santen, IKERVIS\u00ae 1 mg\/mL Eye Drops, Emulsion, 2015 (summary of product characteristics)."},{"key":"10.1016\/j.ejpb.2017.03.006_b0195","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/ICO.0b013e31825e83f4","article-title":"Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits","volume":"32","author":"Daull","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.ejpb.2017.03.006_b0200","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1023\/A:1013671819604","article-title":"Cyclosporine A formulation affects its ocular distribution in rabbits","volume":"19","author":"Kuwano","year":"2002","journal-title":"Pharm. Res."},{"issue":"Pt 4","key":"10.1016\/j.ejpb.2017.03.006_b0205","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/eye.1997.126","article-title":"A comparative approach to topical cyclosporine therapy","volume":"11","author":"Williams","year":"1997","journal-title":"Eye"},{"key":"10.1016\/j.ejpb.2017.03.006_b0210","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/archopht.1989.01070020276038","article-title":"Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops","volume":"107","author":"Kaswan","year":"1989","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0215","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/OPX.0b013e3181824dc4","article-title":"Effect of viscosity on tear drainage and ocular residence time","volume":"85","author":"Zhu","year":"2008","journal-title":"Optom. Vis. Sci."},{"issue":"2015","key":"10.1016\/j.ejpb.2017.03.006_b0220","first-page":"700","article-title":"Collyres de ciclosporine: \u00e9tude d\u2019une cohorte de patients de 2009\u00e0 2013","volume":"38","author":"Kauss Hornecker","year":"2009","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0225","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1034\/j.1600-0420.1999.770217.x","article-title":"Toxicological evaluation of cyclosporine eyedrops","volume":"77","author":"Knagenhjelm","year":"1999","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0230","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00003226-199403000-00006","article-title":"Influence of topically applied cyclosporine A in olive oil on corneal epithelium permeability","volume":"13","author":"Benitez del Castillo","year":"1994","journal-title":"Cornea"},{"key":"10.1016\/j.ejpb.2017.03.006_b0235","series-title":"Presented at European Symposium on Clinical Pharmacy, Dubrovnik, Croatia","article-title":"Stability of cyclosporine eye drops","author":"Bontemps","year":"2008"},{"key":"10.1016\/j.ejpb.2017.03.006_b0240","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/00006324-199510000-00004","article-title":"Refractive index and osmolality of human tears","volume":"72","author":"Craig","year":"1995","journal-title":"Optom. Vis. Sci."},{"key":"10.1016\/j.ejpb.2017.03.006_b0245","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0181-5512(04)96181-5","article-title":"Cyclosporine 2% eye drops preparation","volume":"27","author":"Chast","year":"2004","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0250","first-page":"221","article-title":"Collyre de ciclosporine 2%: validation d\u2019un conditionnement en poly\u00e9thyl\u00e8ne basse densit\u00e9","volume":"27","author":"Fauvel","year":"2008","journal-title":"J. Pharm. Clin."},{"key":"10.1016\/j.ejpb.2017.03.006_b0255","unstructured":"PubChem Open Chemistry Database, Compound Summary for Cyclosporine (CID 6435893), National Center for Biotechnology Information, 2016."},{"key":"10.1016\/j.ejpb.2017.03.006_b0260","unstructured":"Health Council of the Netherlands, Cyclosporin: Evaluation of the Carcinogenicity and Genotoxicity, 2007."},{"key":"10.1016\/j.ejpb.2017.03.006_b0265","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1470-2045(08)70286-9","article-title":"A review of human carcinogens\u2013Part A: pharmaceuticals","volume":"10","author":"Grosse","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0270","unstructured":"EudraCT 2015\u2013000937-54. Evaluation of the Safety and Efficacy of PAD Ciclosporin in Dry Eye Patients, 2015."},{"key":"10.1016\/j.ejpb.2017.03.006_b0275","unstructured":"F. Steele, An Ophthalmic Composition, World Intellectual Property Organization Patent WO 2012\/123515 A1, 2012."},{"key":"10.1016\/j.ejpb.2017.03.006_b0280","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/BF01521575","article-title":"The behaviour of minute oil droplets encapsulated in a water film","volume":"257","author":"Sebba","year":"1979","journal-title":"Colloid Polym. Sci."},{"key":"10.1016\/j.ejpb.2017.03.006_b0285","unstructured":"Disperse Technologies, Technical Information. <http:\/\/www.disperse-ltd.co.uk\/technical-benefits.html> (accessed May 1, 2016)."},{"key":"10.1016\/j.ejpb.2017.03.006_b0290","unstructured":"M. Praestegaard, F. Steele, F. Gomez, Pharmacokinetic characterization of a novel ocular formulation of ciclosporin, Abstract 5388, in: Presented at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2016, 2016."},{"key":"10.1016\/j.ejpb.2017.03.006_b0295","unstructured":"MC2 Biotek, MC2-03: PADciclo \u2013 a PAD\u2122 Eye Droplet (Cyclosporine) for Dry Eye, 2015."},{"key":"10.1016\/j.ejpb.2017.03.006_b0300","unstructured":"Novaliq, CyclASol\u00ae \u2013 Cyclosporine in SFA for Ophthalmological Application to Treat Dry Eye Syndrome, 2015."},{"key":"10.1016\/j.ejpb.2017.03.006_b0305","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejpb.2014.05.009","article-title":"Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery","volume":"88","author":"Dutescu","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2017.03.006_b0310","unstructured":"Businesswire, Novaliq GmbH Reports Positive Results from CyclASol\u00ae (Cyclosporin Solution) Eye Drops Repeated and Ascending Dose Phase 1 Study, 2014."},{"key":"10.1016\/j.ejpb.2017.03.006_b0315","unstructured":"Businesswire, Novaliq Announces Positive Topline Results of Phase 2 Clinical Trial Evaluating CyclASol\u00ae in Adults with Moderate to Severe Dry Eye Disease, 2016."},{"key":"10.1016\/j.ejpb.2017.03.006_b0320","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1089\/jop.2015.0048","article-title":"Semifluorinated alkane eye drops for treatment of dry eye disease\u2013a prospective, multicenter noninterventional study","volume":"31","author":"Steven","year":"2015","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2017.03.006_b0325","unstructured":"Apidel, Licensing Opportunity, 2015."},{"key":"10.1016\/j.ejpb.2017.03.006_b0330","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pharma.2011.01.001","article-title":"Colloidal systems for the delivery of cyclosporin A to the anterior segment of the eye","volume":"69","author":"Di Tommaso","year":"2011","journal-title":"Ann. Pharm. Fr."},{"key":"10.1016\/j.ejpb.2017.03.006_b0335","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejpb.2010.09.012","article-title":"Novel cyclosporin A formulations using MPEG-hexyl-substituted polylactide micelles: a suitability study","volume":"77","author":"Mondon","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2017.03.006_b0340","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1167\/iovs.11-8829","article-title":"A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation","volume":"53","author":"Di Tommaso","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2017.03.006_b0345","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijpharm.2011.01.004","article-title":"Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers","volume":"416","author":"Di Tommaso","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.03.006_b0350","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2012.02.014","article-title":"Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies","volume":"81","author":"Di Tommaso","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2017.03.006_b0355","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ophtha.2012.09.035","article-title":"A novel cyclosporine a drug-delivery system for prevention of human corneal rejection after high-risk keratoplasty: a clinical study","volume":"120","author":"Shi","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2017.03.006_b0360","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0378-5173(99)00003-4","article-title":"Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention","volume":"180","author":"Felt","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.03.006_b0365","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0378-5173(01)00760-8","article-title":"Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface: application to cyclosporin A","volume":"224","author":"De Campos","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.03.006_b0370","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/02652048.2013.805839","article-title":"Chitosan nanoparticles for ocular delivery of cyclosporine A","volume":"31","author":"Basaran","year":"2014","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejpb.2017.03.006_b0375","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.survophthal.2003.12.009","article-title":"Determinants of eye drop size","volume":"49","author":"Van Santvliet","year":"2004","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0380","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejpb.2012.05.003","article-title":"Full factorial design, physicochemical characterisation and biological assessment of cyclosporine A loaded cationic nanoparticles","volume":"82","author":"Hermans","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2017.03.006_b0385","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3109\/1061186X.2012.723214","article-title":"Ocular delivery of cyclosporine A based on glyceryl monooleate\/poloxamer 407 liquid crystalline nanoparticles: preparation, characterization, in vitro corneal penetration and ocular irritation","volume":"20","author":"Chen","year":"2012","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2017.03.006_b0390","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jconrel.2009.04.021","article-title":"Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery","volume":"137","author":"Shen","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2017.03.006_b0395","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijpharm.2010.10.008","article-title":"Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution","volume":"402","author":"Shen","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.03.006_b0400","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3109\/02713680903261405","article-title":"Cyclosporine A-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes","volume":"34","author":"Gokce","year":"2009","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ejpb.2017.03.006_b0405","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.exer.2008.04.002","article-title":"Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea","volume":"87","author":"Yenice","year":"2008","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejpb.2017.03.006_b0410","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.2042-7158.1996.tb03911.x","article-title":"Improved ocular bioavailability of indomethacin by novel ocular drug carriers","volume":"48","author":"Calvo","year":"1996","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0415","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijpharm.2015.07.040","article-title":"Development of a cyclodextrin-based aqueous cyclosporin A eye drop formulations","volume":"493","author":"Johannsdottir","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.03.006_b0420","unstructured":"EMA\/CHMP\/333892\/2013 \u2013 Background Review for Cyclodextrins used as Excipients in the Context of the Revision of the Guideline on \u2018Excipients in the label and package leaflet of medicinal products for human use\u2019 (CPMP\/463\/00 Rev. 1)."},{"key":"10.1016\/j.ejpb.2017.03.006_b0425","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1021\/acs.molpharmaceut.6b00445","article-title":"Prolonged ocular retention of mucoadhesive nanoparticle eye drop formulation enables treatment of eye diseases using significantly reduced dosage","volume":"13","author":"Liu","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2017.03.006_b0430","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0161-6420(93)31558-7","article-title":"Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye","volume":"100","author":"Milani","year":"1993","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2017.03.006_b0435","unstructured":"International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline. Impurities: Guideline for Residual Solvents Q3C (R5), 2011."},{"key":"10.1016\/j.ejpb.2017.03.006_b0440","first-page":"365","article-title":"Characterization and stability studies of a novel liposomal cyclosporin A prepared using the supercritical fluid method: comparison with the modified conventional Bangham method","volume":"8","author":"Karn","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2017.03.006_b0445","first-page":"3791","article-title":"Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsion","volume":"9","author":"Karn","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2017.03.006_b0450","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3109\/10717544.2011.621994","article-title":"Low molecular weight chitosan-coated liposomes for ocular drug delivery: in vitro and in vivo studies","volume":"19","author":"Li","year":"2012","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2017.03.006_b0455","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3109\/02713683.2012.660595","article-title":"Safety evaluation of nanoliposomes containing cyclosporine a after ocular administration","volume":"37","author":"Mosallaei","year":"2012","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ejpb.2017.03.006_b0460","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/ICO.0b013e3182a7f3bf","article-title":"Self-assembling colloidal system for the ocular administration of cyclosporine A","volume":"33","author":"Luschmann","year":"2014","journal-title":"Cornea"},{"key":"10.1016\/j.ejpb.2017.03.006_b0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.4.3.1","article-title":"Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery","volume":"4","author":"Cholkar","year":"2015","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0470","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijpharm.2012.11.009","article-title":"Technology of stable, prolonged-release eye-drops containing cyclosporine A, distributed between lipid matrix and surface of the solid lipid microspheres (SLM)","volume":"441","author":"Wolska","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.03.006_b0475","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijpharm.2008.08.004","article-title":"Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results","volume":"365","author":"Gan","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.03.006_b0480","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3109\/10717544.2013.861883","article-title":"Formulation and evaluation of cyclosporin A emulgel for ocular delivery","volume":"22","author":"Shen","year":"2014","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2017.03.006_b0485","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejpb.2015.05.016","article-title":"Hydrogels in ophthalmic applications","volume":"95","author":"Kirchhof","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2017.03.006_b0490","first-page":"3587","article-title":"Enhanced and sustained topical ocular delivery of cyclosporine A in thermosensitive hyaluronic acid-based in situ forming microgels","volume":"8","author":"Wu","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2017.03.006_b0495","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.4155\/tde.14.75","article-title":"Advances in ophthalmic drug delivery","volume":"5","author":"Morrison","year":"2014","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ejpb.2017.03.006_b0500","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijpharm.2008.05.028","article-title":"Ophthalmic delivery of cyclosporine A from Brij-97 microemulsion and surfactant-laden p-HEMA hydrogels","volume":"361","author":"Kapoor","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.03.006_b0505","series-title":"Biomaterials Science: An Introduction to Materials in Medicine","author":"Ratner","year":"1996"},{"key":"10.1016\/j.ejpb.2017.03.006_b0510","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jconrel.2011.06.028","article-title":"Extended cyclosporine delivery by silicone-hydrogel contact lenses","volume":"154","author":"Peng","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2017.03.006_b0515","first-page":"1008","article-title":"Pilocarpine ocular inserts","volume":"15","author":"Bensinger","year":"1976","journal-title":"Invest. Ophthalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0520","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jcis.2010.03.037","article-title":"Drug transport in HEMA conjunctival inserts containing precipitated drug particles","volume":"347","author":"Gupta","year":"2010","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ejpb.2017.03.006_b0525","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/jop.2006.22.121","article-title":"Therapeutic and toxicological evaluations of cyclosporine a microspheres as a treatment vehicle for uveitis in rabbits","volume":"22","author":"He","year":"2006","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2017.03.006_b0530","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1167\/iovs.05-1373","article-title":"Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study","volume":"47","author":"He","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2017.03.006_b0535","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1638\/06-021.1","article-title":"Sustained release cyclosporine therapy for bilateral keratoconjunctivitis sicca in a red wolf (Canis rufus)","volume":"37","author":"Acton","year":"2006","journal-title":"J. Zoo Wildl. Med."},{"key":"10.1016\/j.ejpb.2017.03.006_b0540","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1167\/iovs.04-1076","article-title":"Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease","volume":"46","author":"Kim","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2017.03.006_b0545","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1167\/iovs.06-0985","article-title":"A pharmacokinetic and safety evaluation of an episcleral cyclosporine implant for potential use in high-risk keratoplasty rejection","volume":"48","author":"Lee","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.ejpb.2017.03.006_b0550","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/vop.12087","article-title":"Treatment of immune-mediated keratitis in horses with episcleral silicone matrix cyclosporine delivery devices","volume":"17","author":"Gilger","year":"2014","journal-title":"Vet. Ophthalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0555","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1167\/iovs.02-1112","article-title":"Pharmacokinetic and toxicity study of an intraocular cyclosporine DDS in the anterior segment of rabbit eyes","volume":"44","author":"Theng","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2017.03.006_b0560","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s00417-005-0109-1","article-title":"Intravitreal implantation of the biodegradable cyclosporin A drug delivery system for experimental chronic uveitis","volume":"244","author":"Dong","year":"2006","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0565","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1167\/iovs.05-1540","article-title":"A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis","volume":"47","author":"Gilger","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2017.03.006_b0570","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijpharm.2012.12.033","article-title":"A new drug delivery system inhibits uveitis in an animal model after cataract surgery","volume":"443","author":"Eperon","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2017.03.006_b0575","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0181-5512(06)73780-9","article-title":"Cytotoxicity evaluation of different eyes drops with cyclosporine oral solution (Sandimmun)","volume":"29","author":"Nourry","year":"2006","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0580","first-page":"263","article-title":"Intraocular absorption of cyclosporin A eyedrops","volume":"15","author":"Minguez","year":"1992","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0585","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s004170050204","article-title":"Topical cyclosporin A in Thygeson's superficial punctate keratitis","volume":"237","author":"Reinhard","year":"1999","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.ejpb.2017.03.006_b0590","unstructured":"V. Leconte-Astruc, P.Y. Robert, P. Marquet, V. Ratsimbazafy, Mise au point de formes gal\u00e9niques de ciclosporine \u00e0 usage oculaire, in: Presented at 9\u00e8me congr\u00e8s de la Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacie Clinique, Marseille, 2000."},{"key":"10.1016\/j.ejpb.2017.03.006_b0595","doi-asserted-by":"crossref","unstructured":"A. Borel, E. Albertini, N. Bonnin, C. Bontemps, A. Boyer, J. Chopineau, F. Chiambaretta, Une nouvelle ciclosporine A 1% et 2%: toxicit\u00e9, tol\u00e9rance et observance, Abstract 7581, in: Presented at Soci\u00e9t\u00e9 Fran\u00e7aise d'Ophtalmologie (SFO), Paris, 2009.","DOI":"10.1016\/S0181-5512(09)73705-2"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641116309080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641116309080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T18:09:20Z","timestamp":1568916560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641116309080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":119,"alternative-id":["S0939641116309080"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2017.03.006","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2017.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}